Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 9;22(5):1265–1273. doi: 10.1158/1078-0432.CCR-15-1186

Figure 2. Relapse-free survival data for.

Figure 2

A182 patients with stage I NSGCT managed by surveillance with the MRC TE08 and TE22 clinical trials, stratified by vascular invasion (VI) and immunohistochemistry for CXCL12 in combination with the presence/absence of histological VI (stratified log rank test p=0.006). B 177 patients with stage I NSGCT managed with surveillance stratified by %EC and VI, illustrated using optimal cut-offs for %EC.